|
1）Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21
|
|
|
|
2）McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-847
|
|
|
|
|
|
3）Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 1998; 95: 9424-9
|
|
|
|
|
|
4）Ronzaud C, Loffing J, Bleich M, et al. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007; 18: 1679-87
|
|
|
|
|
|
5）Ronzaud C, Loffing J, Gretz N, et al. Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am J Physiol Renal Physiol. 2011; 300: F756-60
|
|
|
|
|
|
6）Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005; 111: 3025-33
|
|
|
|
|
|
7）Lother A, Berger S, Gilsbach R, et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011; 57: 746-54
|
|
|
|
|
|
8）Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011; 123: 400-8
|
|
|
|
|
|
9）Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009; 54: 537-43
|
|
|
|
|
|
10）Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010; 120: 3350-64
|
|
|
|
|
|
11）Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012; 153: 3416-25
|
|
|
|
|
|
12）Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010; 24: 2454-63
|
|
|
|
|
|
13）McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012; 18: 1429-33
|
|
|
|
|
|
14）Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 542-51
|
|
|
|
|
|
15）Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012; 14: 668-75
|
|
|
|
|
|
16）Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011; 32: 820-8
|
|
|
|
|
|
17）Irita J, Okura T, Jotoku M, et al. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol. 2011; 301: F833-44
|
|
|
|
|
|
18）Ogawa Y, Mukoyama M, Yokoi H, et al. Natriuretic peptide receptor guanylyl cyclase-a protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012; 23: 1198-209
|
|
|
|
|
|
19）Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012; 59: 324-30
|
|
|
|
|
|
20）Fu Y, Hall JE, Lu D, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension. 2012; 59: 599-606
|
|
|
|
|
|
21）Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009; 20: 2493-502
|
|
|
|
|
|
22）Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011; 121: 2181-96
|
|
|
|
|
|
23）Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011; 121: 2197-209
|
|
|
|
|
|
24）Whaley-Connell AT, Habibi J, Nistala R, et al. Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol. 2012; 35: 90-100
|
|
|
|
|
|
25）Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002; 161: 1773-81
|
|
|
|
|
|
26）Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13: 189-97
|
|
|
|
|
|
27）Zhang A, Jia Z, Wang N, et al. Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int. 2011; 80: 51-60
|
|
|
|
|
|
28）Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARgamma. Am J Pathol. 2011; 178: 2020-31
|
|
|
|
|
|
29）He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011; 17: 1610-8
|
|
|
|
|
|
30）Pisoni R, Acelajado MC, Cartmill FR, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012; 26: 502-6
|
|
|
|
|
|
31）Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5: 1380-7
|
|
|
|
|
|
32）Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol. 2010; 33: 604-8
|
|
|
|
|
|
33）Jaffe IZ, Newfell BG, Aronovitz M, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010; 120: 3891-900
|
|
|
|
|
|
34）Onoue K, Uemura S, Takeda Y, et al. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation. 2009; 120: 2470-7
|
|
|
|
|
|
35）Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nature Medicine. 2008; 14: 1370-6
|
|
|
|
|
|
36）Kawarazaki W, Nagase M, Yoshida S, et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol. 2012; 23: 997-1007
|
|
|
|
|
|
37）Shibata S, Mu S, Kawarazaki H, et al. Rac1 GT Pase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011; 121: 3233-43
|
|
|
|
|
|
38）Massaad C, Houard N, Lombes M, et al. Modulation of human mineralocorticoid receptor function by protein kinase A. Mol Endocrinol. 1999; 13: 57-65
|
|
|
|
|
|
39）Le Moellic C, Ouvrard-Pascaud A, Capurro C, et al. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol. 2004; 15: 1145-60
|
|
|
|
|
|
40）Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010
|
|
|
|
|
|
41）Murai-Takeda A, Shibata H, Kurihara I, et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J Biol Chem. 2010; 285: 8084-93
|
|
|
|
|
|
42）Luther JM, Luo P, Wang Z, et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int. 2012; 82: 643-51
|
|
|
|
|
|
43）Lauterburg M, Escher G, Dick B, et al. Uninephrectomy reduces 11beta-hydroxysteroid dehydrogenase type 1 and type 2 concomitantly with an increase in blood pressure in rats. J Endocrinol. 2012; 214: 373-80
|
|
|
|
|
|
44）Toyonaga J, Tsuruya K, Ikeda H, et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011; 26: 2475-84
|
|
|
|
|
|
45）Kitada K, Nakano D, Liu Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in dahl salt-sensitive rats. PLoS One. 2012; 7: e41896
|
|
|
|
|
|
46）Ruhs S, Stratz N, Schlor K, et al. Modulation of transcriptional mineralocorticoid receptor activity by nitrosative stress. Free Radic Biol Med. 2012; 53: 1088-100
|
|
|
|
|
|
47）Takeda Y, Yoneda T, Demura M, et al. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002; 105: 677-9
|
|
|
|
|
|
48）Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215-28
|
|
|
|
|
|
49）Seiferth A, Ruhs S, Mildenberger S, et al. The phosphatase calcineurin PP2BAbeta mediates part of mineralocorticoid receptor transcriptional activity. FASEB J. 2012; 26: 2327-37
|
|
|
|
|
|
50）Karpushev AV, Levchenko V, Ilatovskaya DV, et al. Novel role of Rac1/WAVE signaling mechanism in regulation of the epithelial Na+ channel. Hypertension. 2011; 57: 996-1002
|
|
|
|
|
|
51）Pavlov TS, Chahdi A, Ilatovskaya DV, et al. Endothelin-1 inhibits the epithelial Na+ channel through betaPix/14-3-3/Nedd4-2. J Am Soc Nephrol. 2010; 21: 833-43
|
|
|
|
|
|
52）Hori K, Nagai T, Izumi Y, et al. Vasopressin V1a receptor is required for nucleocytoplasmic transport of mineralocorticoid receptor. Am J Physiol Renal Physiol. 2012; 303: F1080-8
|
|
|
|
|